Under the drive of great interest in percutaneous technologies, transcatheter treatment of mitral regurgitation has been developed in recent years and it is, at the moment, clinically used in the form of the MitraClip system, particularly in the setting of functional mitral regurgitation. This article presents the 12-month results of the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) II trial, the randomized prospective study of MitraClip percutaneous treatment and surgical treatment of mitral regurgitation. Percutaneous repair appeared less effective than conventional surgery (percutaneous freedom from death, mitral surgery and recurrent mitral regurgitation 55% vs. 73% for surgery), but it was associated with superior safety in patients often more compromised (any major adverse event at 30 days 15% vs. 48% for surgery, although this was influenced mostly by transfusions) and similar improvements in clinical outcomes. Today, percutaneous mitral valve repair through the MitraClip device has the notable ability of guarantee clinical improvements and relief from symptoms in high-risk patients who would not otherwise receive an open surgical treatment. Nevertheless, several issues remain, particularly the durability of the results and therefore the future of the procedure itself, even considering the upcoming possibility of percutaneous mitral valve replacement. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Alberto Pozzoli, Michele De Bonis, and Ottavio Alfieri.